hp and UniQure have launched genetic control technology the companies hope will improve the effectiveness and precision of gene therapy in liver treatment . Tests have shown the technology is eight times better than the standard technology , RTS . To switching genes on or off , RTS uses molecules that can be treated as foreign because they are not naturally present in the body . Synpromics ’ technology uses small molecules used by the US Food and Drug Administration as well . The liver is a popular target for gene therapy . Controlling the gene expression location could help avoid side effects and enable lower doses .
Synpromics and UniQure have launched genetic control technology the companies hope will improve the safety and precision of gene therapy in liver treatment. Tests have shown the technology is eight times better than the standard system, RTS. To switch genes on or off, RTS uses molecules that can be treated as foreign because they are not naturally present in the body. Synpromics’ technology uses small molecules approved by the US Food and Drug Administration as drugs. The liver is a popular target for gene therapy. Controlling the gene expression location could help avoid side effects and enable lower doses.